TY - JOUR
T1 - Health-related quality of life and health utility score of patients with gastric cancer
T2 - a multi-centre cross-sectional survey in China
AU - Xia, Ruyi
AU - Zeng, Hongmei
AU - Liu, Qian
AU - Liu, Shuzheng
AU - Zhang, Zhiyi
AU - Liu, Yuqin
AU - Guo, Guizhou
AU - Song, Guohui
AU - Zhu, Yigong
AU - Wu, Xianghong
AU - Song, Bingbing
AU - Liao, Xianzhen
AU - Chen, Yanfang
AU - Wei, Wenqiang
AU - Chen, Gang
AU - Chen, Wanqing
AU - Zhuang, Guihua
PY - 2020/11
Y1 - 2020/11
N2 - Objective: To evaluate the health-related quality of life (HRQoL) and health state utility scores of gastric cancer patients in daily life at different clinical stages after treatment, and to explore influencing factors associated with HRQoL. Methods: Gastric cancer patients discharged from hospitals and healthy controls identified by screening were recruited. The three-level EQ-5D was employed to assess HRQoL and was scored using two Chinese-specific tariffs published in 2014 and 2018. Results: A total of 1,399 patients and 2,179 healthy controls were recruited. The likelihood of reporting problems in the five dimensions for patients was 4.0–23.8 times higher than controls. Based on the 2014/2018 tariff, the mean EQ-5D utility score was 0.321/0.163 lower than controls, and the mean utility scores of each patient subgroup were 0.077/0.039 (high-grade intraepithelial neoplasia/carcinoma in situ), 0.254/0.121 (Stage I), 0.249/0.123 (Stage II), 0.353/0.182 (Stage III) and 0.591/0.309 (Stage IV) lower than controls (all statistically significant). Age, occupation, duration of illness, other chronic disease status and therapeutic regimen had a significant impact upon different aspects of HRQoL in patients. Conclusions: Gastric cancer significantly impaired patients' HRQoL in daily life after treatment. More advanced cancer stages were associated with larger decrements on health state utility.
AB - Objective: To evaluate the health-related quality of life (HRQoL) and health state utility scores of gastric cancer patients in daily life at different clinical stages after treatment, and to explore influencing factors associated with HRQoL. Methods: Gastric cancer patients discharged from hospitals and healthy controls identified by screening were recruited. The three-level EQ-5D was employed to assess HRQoL and was scored using two Chinese-specific tariffs published in 2014 and 2018. Results: A total of 1,399 patients and 2,179 healthy controls were recruited. The likelihood of reporting problems in the five dimensions for patients was 4.0–23.8 times higher than controls. Based on the 2014/2018 tariff, the mean EQ-5D utility score was 0.321/0.163 lower than controls, and the mean utility scores of each patient subgroup were 0.077/0.039 (high-grade intraepithelial neoplasia/carcinoma in situ), 0.254/0.121 (Stage I), 0.249/0.123 (Stage II), 0.353/0.182 (Stage III) and 0.591/0.309 (Stage IV) lower than controls (all statistically significant). Age, occupation, duration of illness, other chronic disease status and therapeutic regimen had a significant impact upon different aspects of HRQoL in patients. Conclusions: Gastric cancer significantly impaired patients' HRQoL in daily life after treatment. More advanced cancer stages were associated with larger decrements on health state utility.
KW - China
KW - EQ-5D
KW - gastric cancer
KW - health state utility
KW - health-related quality of life
UR - http://www.scopus.com/inward/record.url?scp=85087165112&partnerID=8YFLogxK
U2 - 10.1111/ecc.13283
DO - 10.1111/ecc.13283
M3 - Article
C2 - 32602238
AN - SCOPUS:85087165112
SN - 0961-5423
VL - 29
JO - European Journal of Cancer Care
JF - European Journal of Cancer Care
IS - 6
M1 - e13283
ER -
